EMA to Hold its Second Public Meeting on COVID-19 Vaccines
The agency is organizing a second public meeting on January 8, 2021 to discuss the assessment, approval, and roll-out of new COVID-19 vaccines.
The European Medicines Agency (EMA) is organizing a second public meeting regarding the assessment, approval, and roll-out of new COVID-19 vaccines. At the meeting, EMA will discuss plans to ensure the safety of COVID-19 vaccines and the roles that the European Commission and the national public health authorities will play in the roll-out of the vaccines, according to a press release dated Dec. 22, 2020.
The meeting will be held online on January 8 and will be attended by EMA executive director Emer Cooke and members of EMA’s human medicines and safety committees, among others. An online form is being made available for those who wish to submit questions to panelists at the meeting. The agency has requested that these questions be submitted by Dec. 31, 2020.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
